According to the Center for Disease Control and Prevention (CDC), surveillance systems are detecting a slow but steady increase in influenza (flu). Without the right diagnostic tools, it is very hard to distinguish flu from other viral or bacterial illnesses. As the presence of other respiratory infections rapidly increase due to COVID-19 and other variants, flu screening is more important than ever before.
Ensuring your practice is properly prepared with testing and treatment options is the safest way to provide quality care and a reliable action plan for your patients.
Henry Schein Medical offers a robust portfolio of flu testing options that can be administered and read at the point-of-care. With rapid results in minutes, rather than hours and days, it may be possible for you to:
The CDC states "Influenza virus testing can inform clinical management when the results may influence clinical decisions such as whether to initiate antiviral treatment, perform other diagnostic testing, or to implement infection prevention and control measures for influenza." Whether it's the flu, COVID-19, or another respiratory illness, accurately diagnosing your patients is at the heart of your treatment plan.
Our flu test portfolio includes molecular, reader and lateral flow options:
ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The unique ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing you to make effective clinical decisions sooner.
Unlock the Power of PCR at Point of Care
The Cepheid GeneXpert Xpress brings the power of CLIA-waived PCR testing to the physician office lab and beyond.
This fast and accurate solution streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. The system can help detect infectious diseases such as influenza A and B, respiratory syncytial virus (RSV), and group A strep while the patient is still on site, which can enable faster decision-making for an earlier intervention opportunity.
This CLIA-waived test uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and B viral nucleoprotein antigens in nasal and nasopharyngeal swab and nasopharyngeal aspirate/wash specimens taken directly from symptomatic patients.
Accurately reads and interprets lateral flow tests in just seconds, delivering automated, objective results in any health-care setting. It is a camerabased instrument that will detect the presence of, and identify a completed lateral flow assay, analyze the intensity of the test and control line, and display the results (positive, negative, or invalid) on the color touch screen.
The Acucy™ Influenza A&B Test on the Acucy™ System provides clinicians flexibility in workflow and accurate, standardized results for improved patient care.
Intended for the qualitative detection of influenza type A and type B nucleoprotein antigens directly from nasal and nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection.
An immunoassay for detecting influenza types A and B. Three simple steps with results in 10 minutes or less. Color-coded procedure card helps demonstrate each step of test. Kit contains positive and negative controls, and stores at room temperature.